Astrazeneca (AZN) Cost of Revenue (2009 - 2026)

Astrazeneca has reported Cost of Revenue for 18 years, with the latest figure at $2.5 billion in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 2.02% year-over-year to $2.5 billion in Q2 2026; TTM through Jun 2026 was $18.6 billion, a 77.14% increase from a year earlier, with the FY2025 full-year figure at $10.6 billion, up 4.17% from the prior year.
• Cost of Revenue was $2.5 billion for Q2 2026 at Astrazeneca, down from $2.7 billion in the prior quarter.
• The five-year high for Cost of Revenue was $10.6 billion in Q4 2025, with the low at $1.9 billion in Q1 2023.
• Average Cost of Revenue over 5 years is $3.2 billion, with a median of $2.7 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue plunged 54.28% in 2024, then surged 290.2% in 2025.
• Over 5 years, Cost of Revenue stood at $2.9 billion in 2022, then jumped by 105.52% to $6.0 billion in 2023, then slumped by 54.28% to $2.7 billion in 2024, then soared by 290.2% to $10.6 billion in 2025, then slumped by 76.27% to $2.5 billion in 2026.
• The last three Cost of Revenue figures came in at $2.5 billion (Q2 2026), $2.7 billion (Q1 2026), and $10.6 billion (Q4 2025), per Business Quant data.